Openbookopenbook
Equity
Poxel S.A.(0RA2)
EUR --+0.00%
Reward35Moderate
Risk89High
📊75%Data
Thin -178% profit margin · Revenue growing 88% YoY
0RA2
+0.0 · +0.00%
EUR · LSE
Poxel S.A. |
Structurally Challenged
Market Cap:39.50M
ℹ️
Reward Rating
35
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
89
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0RA2 to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Poxel S.A.?

, a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases.

0RA2 · Verdict

Limited reward · high risk

0RA2's standout is valuation; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

0RA2 · Verdict

What’s working & what to watch

Strengths 1

  • Valuation67/100

    Above average

Watchouts 5

  • Cash flow5/100

    -276% net margin

  • Balance sheet7/100

    Current ratio 0.78

  • Growth15/100

    Rev -20.9% CAGR · earnings -8.3%

  • Volatility20/100

    Weak vs peers

  • Profitability32/100

    -276% net margin · -323% ROE

Model-based scoring. For information only — not financial advice.

What is Poxel S.A.?

, a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company is listed on the LSE in UK, with a market capitalisation of 39.50M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (35)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap39.50M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.829
52 Week Low0.219
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding24M
No. of Employees5
IndustryN/A
ExchangeLSE
Beta1.539
CurrencyEUR
Websitewww.poxelpharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.